Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of “Reduce” by Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have received an average recommendation of “Reduce” from the nineteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, sixteen have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $16.06.

A number of research analysts have recently weighed in on SAGE shares. Robert W. Baird lowered their price objective on Sage Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. The Goldman Sachs Group dropped their price target on shares of Sage Therapeutics from $19.00 to $11.00 and set a “neutral” rating for the company in a research report on Friday, July 26th. JPMorgan Chase & Co. reduced their price objective on shares of Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. Mizuho lowered their target price on shares of Sage Therapeutics from $18.00 to $16.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Finally, Scotiabank cut their price target on Sage Therapeutics from $19.00 to $17.00 and set a “sector outperform” rating for the company in a research note on Thursday, July 25th.

Sage Therapeutics Trading Up 6.4 %

SAGE opened at $7.83 on Monday. The firm’s 50 day simple moving average is $9.40 and its two-hundred day simple moving average is $12.66. The company has a market capitalization of $478.02 million, a PE ratio of -0.93 and a beta of 0.91. Sage Therapeutics has a 1-year low of $7.19 and a 1-year high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The company had revenue of $8.65 million during the quarter, compared to analysts’ expectations of $8.85 million. During the same quarter last year, the company earned ($2.68) earnings per share. The company’s revenue for the quarter was up 249.8% on a year-over-year basis. Equities analysts forecast that Sage Therapeutics will post -6.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Sage Therapeutics by 8.1% during the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock valued at $107,781,000 after purchasing an additional 432,013 shares during the last quarter. RTW Investments LP increased its holdings in shares of Sage Therapeutics by 0.9% in the 4th quarter. RTW Investments LP now owns 5,197,019 shares of the biopharmaceutical company’s stock worth $112,619,000 after buying an additional 47,537 shares during the last quarter. Bellevue Group AG raised its position in shares of Sage Therapeutics by 27.1% during the 1st quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock valued at $83,684,000 after buying an additional 952,193 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Sage Therapeutics by 69.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock valued at $15,217,000 after acquiring an additional 333,805 shares during the last quarter. Finally, Federated Hermes Inc. bought a new position in shares of Sage Therapeutics in the 2nd quarter valued at about $7,281,000. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.